Stockscreener 앱 받기
8.615
6.80%
-0.655
전일 마감가:
$9.27
열려 있는:
$9.29
하루 거래량:
2.18M
Relative Volume:
1.91
시가총액:
$739.98M
수익:
-
순이익/손실:
$-48.17M
주가수익비율:
-15.11
EPS:
-0.57
순현금흐름:
$-37.10M
1주 성능:
-10.09%
1개월 성능:
-7.79%
6개월 성능:
-2.48%
1년 성능:
+60.59%
1일 변동 폭
$8.34
$9.29
1주일 범위
$8.34
$10.38
52주 변동 폭
$5.22
$14.44
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
명칭
Anavex Life Sciences Corporation
전화
844-689-3939
주소
630 5TH AVENUE, NEW YORK
AVXL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
8.615 | 796.24M | 0 | -48.17M | -37.10M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.62 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.43 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
559.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
802.13 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.64 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-12-06 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-09-23 | 개시 | BTIG Research | Buy |
| 2020-12-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-09-28 | 개시 | Ladenburg Thalmann | Buy |
| 2020-02-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-06-18 | 개시 | Janney | Buy |
| 2018-05-16 | 재개 | Maxim Group | Buy |
| 2018-03-08 | 개시 | ROTH Capital | Buy |
| 2018-02-13 | 재확인 | Maxim Group | Buy |
| 2017-09-29 | 재개 | Noble Financial | Buy |
| 2017-02-07 | 개시 | Noble Financial | Buy |
| 2016-03-29 | 개시 | FBR Capital | Outperform |
모두보기
Anavex Life Sciences Corporation 주식(AVXL)의 최신 뉴스
How strong is Anavex Life Sciences Corp. stock revenue growthWeekly Investment Recap & Weekly High Conviction Ideas - newser.com
Detecting price anomalies in Anavex Life Sciences Corp. with AIJuly 2025 Reactions & Fast Exit/Entry Strategy Plans - newser.com
Real time breakdown of Anavex Life Sciences Corp. stock performanceMarket Sentiment Report & Fast Entry High Yield Stock Tips - newser.com
Can trapped investors hope for a rebound in Anavex Life Sciences Corp.July 2025 Sentiment & Long-Term Safe Investment Plans - newser.com
How Anavex Life Sciences Corp. stock valuations compare to rivalsJuly 2025 Update & AI Powered Market Entry Strategies - newser.com
Heatmap analysis for Anavex Life Sciences Corp. and competitorsWeekly Stock Summary & Safe Entry Zone Identification - newser.com
Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’ - The Manila Times
Anavex Life Sciences Corp. Announces Oral Presentation on Alzheimer's Disease Care at Alzheimer Europe Conference - Quiver Quantitative
Oral Blarcamesine Presented at 35th Alzheimer Europe — Anavex Highlights ANAVEX®2-73-AD-004 IIb/III - Stock Titan
Will Anavex Life Sciences Corp. (12X1) stock keep high P E multiplesJuly 2025 Analyst Calls & Growth Focused Investment Plans - newser.com
Is Anavex Life Sciences Corp. (12X1) stock testing key supportWeekly Trade Report & Community Verified Trade Alerts - newser.com
Anavex Life Sciences (NASDAQ:AVXL) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Anavex Life Sciences (NASDAQ:AVXL) Receives Buy Rating from HC Wainwright - MarketBeat
HC Wainwright & Co. Reiterates Anavex Life Sciences (AVXL) Buy Recommendation - Nasdaq
Anavex Life Sciences stock rating reiterated at Buy by H.C. Wainwright - Investing.com
How Anavex Life Sciences Corp. stock reacts to global recession fearsBreakout Watch & Low Drawdown Momentum Ideas - newser.com
Long term hold vs stop loss in Anavex Life Sciences Corp.Analyst Downgrade & Community Consensus Stock Picks - newser.com
Tools to monitor Anavex Life Sciences Corp. recovery probabilityEarnings Risk Report & Advanced Technical Signal Analysis - newser.com
Anavex Life Sciences (NASDAQ:AVXL) Trading Up 8.7%Should You Buy? - MarketBeat
Anavex Life Sciences (Nasdaq:AVXL) Reports Positive Phase 2 Results for ANAVEX®3-71 in Schizophrenia - Kalkine Media
D. Boral Capital Maintains Anavex Life Sciences (AVXL) Buy Recommendation - Nasdaq
Is Anavex Life Sciences Corp a good long term investmentBollinger Bands Signals & Free Phenomenal Capital Appreciation - earlytimes.in
Anavex: ANAVEX 3-71 Could Potentially Offer Disease-Modifying Effects For Schizophrenia - Seeking Alpha
Anavex Life Sciences (NASDAQ:AVXL) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Anavex Life Sciences (AVXL): Analyst Reaffirms "Buy" Rating | AV - GuruFocus
Anavex Life Sciences Stock Just Shot Up 7% Today – Here’s An Important Update - Stocktwits
Anavex Life Sciences (AVXL) Shares Rise on Positive Trial Result - GuruFocus
Anavex Life Sciences Reports Positive Phase 2 Results for ANAVEX®3-71 in Schizophrenia Clinical Study Achieving Safety and Tolerability Endpoints - Quiver Quantitative
Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program - The Manila Times
Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia - The Manila Times
Anavex Life Sciences stock rises after positive schizophrenia drug trial - Investing.com
Anavex Develops Once-Daily Tablet for ANAVEX3-71 in Phase 1b Trial | AVXL Stock News - Stock Titan
Novel Schizophrenia Drug ANAVEX3-71 Shows Promise: Safe Profile and Reduced Brain Inflammation Markers - Stock Titan
Anavex Life Sciences (NASDAQ:AVXL) Receives “Buy” Rating from D. Boral Capital - Defense World
Alzheimer’s Disease Market: Epidemiology, Therapies, and Key Players | Anavex Life Sciences Corp., TauRx Therapeutics Ltd, BioVie Inc., AriBio Co., Ltd., Novo Nordisk A/S, AgeneBio, Neurim Pharmaceuti - Barchart.com
Anavex Life Sciences (NASDAQ:AVXL) Earns "Buy" Rating from D. Boral Capital - MarketBeat
Alzheimer's Disease Market: Epidemiology, Therapies, And Key Players Anavex Life Sciences Corp., Taurx Therapeutics Ltd, Biovie Inc., Aribio Co., Ltd., Novo Nordisk A/S, Agenebio, Neurim Pharmaceuti - Menafn.com
Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial - markets.businessinsider.com
Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer's Disease Trial - Investing News Network
Anavex Life Sciences Announces Publication of Oral - GlobeNewswire
70% Success Rate: Anavex's Once-Daily Oral Alzheimer's Drug Shows Breakthrough Results in Late-Stage Trial - Stock Titan
Why millennials buy Anavex Life Sciences Corp. (12X1) stockJuly 2025 PostEarnings & Daily Price Action Insights - newser.com
How to recover losses in Anavex Life Sciences Corp. stockJuly 2025 Drop Watch & Safe Entry Point Identification - newser.com
Real time pattern detection on Anavex Life Sciences Corp. stockMarket Volume Summary & Target Return Focused Stock Picks - newser.com
What drives PRCT stock priceMarket Sentiment Shifts & These 3 Stocks Could Change Your Portfolio - earlytimes.in
What drives Anavex Life Sciences Corp stock priceOptions Trading Strategies & Minimal Capital Growth Plans - earlytimes.in
What analysts say about Anavex Life Sciences Corp stockEquity Performance Review & Stocks With 200% Upside Potential - Early Times
How Anavex Life Sciences Corp. (12X1) stock trades pre earningsJuly 2025 Gainers & Free Safe Entry Trade Signal Reports - newser.com
H.C. Wainwright Reiterates Its ‘Buy’ Rating on Anavex Life Sciences Corp. (AVXL) with a $42 Price Target - Insider Monkey
Anavex Life Sciences Corp. $AVXL Shares Sold by Goldman Sachs Group Inc. - MarketBeat
Published on: 2025-09-22 05:58:42 - newser.com
Anavex Life Sciences Corporation (AVXL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Anavex Life Sciences Corporation 주식 (AVXL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Thomas Steffen | Director |
Jun 05 '25 |
Option Exercise |
1.76 |
50,000 |
88,000 |
55,000 |
| MISSLING CHRISTOPHER U | President and CEO |
Mar 24 '25 |
Option Exercise |
0.92 |
500,000 |
460,000 |
1,750,210 |
1.44%
자본화:
|
볼륨(24시간):